Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection
Abdulaziz Madani,Qais Almuhaideb
DOI: https://doi.org/10.2147/BTT.S317888
2021-09-01
Biologics: Targets and Therapy
Abstract:Abdulaziz Madani, 1 Qais Almuhaideb 2 1 Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2 College of Medicine, King Saud University, Riyadh, Saudi Arabia Correspondence: Abdulaziz Madani King Saud University, Riyadh, 11451, Saudi Arabia Tel +966 1-80 66481 Fax +966114671992 Email Down syndrome is the most common chromosomal disorder and may present with a combination of dysmorphic features, congenital heart disease, and immunological deficiency. The association between Down syndrome and psoriasis is unclear. The prevalence of psoriasis in patients with Down syndrome ranges from 0.5% to 8%. The safety of biologics in the treatment of Down syndrome-related psoriasis is still debated. Down syndrome results in mild immunological abnormalities; consequently, the risk of infectious complications during immunosuppressive therapy might be higher in this group of patients. We report a case of a 33-year-old male, a case of chronic plaque psoriasis, Down syndrome (DS), asthma, and hepatitis B. The patient was started on Calcipotriene 0.005%-betamethasone 0.064% ointment, which failed to control the patient's psoriasis; thus, adalimumab was started. His response to adalimumab was significant, where over 70% improvement of the psoriatic lesions was seen. Keywords: adalimumab, biologics, trisomy 21, HBV Down syndrome (DS), also known as trisomy 21, is a genetic disorder caused by an additional copy of chromosome 21. 1 DS is associated with rare dermatological conditions and an increased frequency of some common dermatoses. 2 Individuals with DS have a higher prevalence of psoriasis, reaching 8%. 3,4 The association between DS and the development of psoriasis and its severity is unclear. 5,6 We report a case of psoriasis in a patient with DS with concomitant hepatitis B virus (HBV) infection that successfully responded to adalimumab. A 33-year-old male with chronic plaque psoriasis since 2009, DS, and asthma with atopy, presented to the Dermatology clinic at King Khalid University Hospital in Riyadh, Saudi Arabia in 2018. At his initial presentation to our clinic, over 10% of his body surface area (BSA) was covered with hyperkeratotic erythematous scaly plaques over his lower limbs, knees, and elbows (Figure 1). The patient was started on topical calcipotriene 0.005%-betamethasone 0.064% ointment daily. Figure 1 Extensive bilateral psoriatic lesions over the knee, anterior leg, and dorsum of the foot. Over the next months, the response to calcipotriene 0.005% betamethasone 0.064% ointment was poor and BSA remained more than 10%. The patient developed bilateral diffuse erythematous scaly plaques over the upper extremities, trunk, and left ear in addition to the bilateral hyperkeratotic plaques over the knees, legs, and foot. The patient underwent screening to start treatment with adalimumab. The screening showed a normal complete blood count and urinalysis; the liver function test was normal except for low albumin (31.38 g/L). The interferon gamma release assay (IGRA) test was negative, and hepatitis C was not detectable by PCR. Hepatitis B screening showed positive hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B core antibody (anti-HBc); negative hepatitis B surface antibody (HBsAb) and hepatitis B e antibody (HBeAb). The patient was started with entecavir 0.5 mg oral daily by the hepatology team. Due to the extensive skin involvement and the lack of improvement with topical treatment, a decision was made to start the patient on a biologic treatment. Given the lack of biologic options in our institution, and after discussion with the hepatology team, a decision was made to start the patient on adalimumab injections. Adalimumab was started in 2020 with a dose of 80 mg, followed by a dose of 40 mg every other week. Two months after treatment, the lesions in the trunk improved by 30% and the lesions in the upper extremities and ears completely cleared up. However, the lesions on the legs and feet did not improve. The patient did not complain of joint pain or stiffness. He had stopped using topical medications, so the topical calcipotriene-betamethasone ointment was reintroduced. Seven months into treatment, the knee, leg, and foot lesions showed an improvement of over 70% (Figure 2), and no joint pain was present. At the time of this writing, the patient was still being treated with adalimumab, entecavir, and topical calcipotriene-betamethasone ointment. Figure 2 Significant improvement in psoriatic lesions after treatment with adalimumab. Psoriasis affects 2.0% to 3.0% of the world's population, while it has been reported to reach 8% in patients with Down syndrome. 3,7 The concomitant presence of th -Abstract Truncated-